This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 8.20% and 44.39%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
by Zacks Equity Research
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
Glaxo Inks Genome Research Deal With University of California
by Zacks Equity Research
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 7.55% and -14.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study
by Zacks Equity Research
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.
Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -10.42% and -36.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch
by Ryan McQueeney
Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Sweta Killa
Sector ETF report for ARKG
Should You Invest in the ARK Innovation ETF (ARKK)?
by Sweta Killa
Sector ETF report for ARKK
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
Should You Invest in the ARK Innovation ETF (ARKK)?
by Zacks Equity Research
Sector ETF report for ARKK
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 8.77% and 20.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
Should You Invest in the ARK Innovation ETF (ARKK)?
by Sweta Killa
Sector ETF report for ARKK
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Zacks Equity Research
Sector ETF report for ARKG
Should You Invest in the ARK Innovation ETF (ARKK)?
by Zacks Equity Research
Sector ETF report for ARKK
Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia
by Zacks Equity Research
Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia
CRISPR Science and Stocks: Knowing Enough to Invest
by Kevin Cook
Can you learn enough about the science and the companies to invest with confidence?
Should You Invest in the ARK Innovation ETF (ARKK)?
by Zacks Equity Research
Sector ETF report for ARKK
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
by Zacks Equity Research
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA
by Zacks Equity Research
FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.